TAS-118(S-1联合亚叶酸钙)对比S-1治疗吉西他滨难治性晚期胰腺癌患者:一项随机、开放标签、3期研究(GRAPE试验)
这项在日本和韩国58个中心开展的随机开放标签3期研究纳入603例吉西他滨难治性转移性胰腺癌患者,随机接受TAS-118或S-1治疗。TAS-118组与S-1组总生存无差异(中位7.6个月对7.9个月,HR 0.98,P=0.756),无进展生存TAS-118组显著更长(中位3.9个月对2.8个月,HR 0.80,P=0.009)。结论为TAS-118未改善总生存。
要点
- TAS-118组与S-1组总生存无差异,中位总生存7.6个月对7.9个月,HR 0.98,P=0.756。
- TAS-118组无进展生存显著长于S-1组,中位3.9个月对2.8个月,HR 0.80,P=0.009。
- 总生存存在日本与韩国之间(P=0.004)及不可切除与复发疾病之间(P=0.025)的交互作用。
核心结论
- 在吉西他滨难治性晚期胰腺癌患者中,TAS-118与S-1相比未改善总生存。
- 需要进一步研究以找出从S-1联合亚叶酸钙中获益的患者。
研究设计与样本
- 随机、开放标签、3期研究,在日本和韩国58个中心开展。
- 共603例患者随机,TAS-118组300例、S-1组301例接受治疗。
- 入组为一线吉西他滨为基础化疗期间进展或术后吉西他滨为基础辅助治疗期间或之后复发的转移性胰腺癌患者。
- 随机1:1接受S-1(40-60 mg,每日两次,6周周期中用4周)或TAS-118(S-1 40-60 mg加亚叶酸钙25 mg,每日两次,2周周期中用1周)。
- 主要终点为总生存。
主要发现
- TAS-118组与S-1组总生存无差异:中位总生存7.6个月对7.9个月,HR 0.98(95%CI 0.82-1.16),P=0.756。
- TAS-118组无进展生存显著长于S-1组:中位3.9个月对2.8个月,HR 0.80(95%CI 0.67-0.95),P=0.009。
- 总生存存在日本与韩国之间的交互作用(P=0.004)。
- 总生存存在不可切除与复发疾病之间的交互作用(P=0.025)。
- 两组不良事件的发生率、特征和严重程度相似。
临床怎么用
- 原文结论为TAS-118与S-1相比未改善总生存,并指出需进一步研究以找出从S-1联合亚叶酸钙中获益的患者。
局限性
- 原文结论指出需要进一步研究以找出从S-1联合亚叶酸钙中获益的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In our previous randomised phase 2 study for patients with gemcitabine-refractory advanced pancreatic cancer, S-1 plus leucovorin improved progression-free survival compared with S-1 alone. Here, we evaluated the efficacy of TAS-118 (S-1 plus leucovorin) versus S-1 in overall survival (OS). PATIENTS AND METHODS: This randomised, open-label, phase 3 study was conducted at 58 centres in Japan and Korea. Patients with metastatic pancreatic cancer that progressed during first-line gemcitabine-based chemotherapy or recurred during or after post-operative gemcitabine-based adjuvant treatment were randomly assigned (1:1) to receive either S-1 (40-60 mg, twice daily for 4 weeks in a 6-week cycle) or TAS-118 (S-1 40-60 mg plus leucovorin 25 mg, twice daily for 1 week in a 2-week cycle). The primary end-point was OS. RESULTS: A total of 603 patients were randomised, and 300 and 301 patients received TAS-118 and S-1, respectively. There was no difference in OS between groups (median OS for TAS-118 versus S-1, 7.6 months versus 7.9 months; hazard ratio [HR], 0.98 [95% confidence interval (CI), 0.82-1.16]; P = 0.756). Progression-free survival was significantly longer with TAS-118 than S-1 (median, 3.9 months versus 2.8 months; HR, 0.80 [95% CI, 0.67-0.95]; P = 0.009). There were interactions between Japan and Korea (P = 0.004) and between unresectable and recurrent disease (P = 0.025) in OS. Incidence, profile and severity of adverse events were similar between groups. CONCLUSION: TAS-118 did not improve OS in patients with gemcitabine-refractory advanced pancreatic cancer compared to S-1. Further studies are needed to find patients who have benefit from adding leucovorin to S-1.
引用
- Ioka T, Ueno M, Ueno H, et al. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial). Eur J Cancer. 2018. PMID: 30471651. doi:10.1016/j.ejca.2018.10.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。